Rozenberg S, Vasquez J B, Vandromme J, Kroll M
Interdisciplinary Group on Osteoporosis, St Peter hospital, Free Universities of Brussels (VUB-ULB), Belgium.
Drugs Aging. 1998 Jul;13(1):33-41. doi: 10.2165/00002512-199813010-00004.
Hormone replacement therapy (HRT) influences many aspects of health: climacteric symptoms, osteoporosis, cardiovascular disease, breast and endometrial cancer, thrombosis and emboli, and Alzheimer's disease. A decision to use HRT may depend on a woman's individual views of the menopausal transition, the postmenopause and its consequences. It is therefore useful that the health provider inquiries about and discusses these issues in a cultural and family context. Health providers and patients should be thoroughly informed about the symptoms associated with hormonal deprivation, the associated risks of osteoporosis and cardiovascular disease, and the potential of HRT to prevent these afflictions. Recent studies suggest that HRT might be particularly beneficial in women who have an increased risk for cardiovascular disease (because of left ventricular hypertrophy, diabetes mellitus, hypertension or hypercholesterolaemia, or because they smoke) or osteoporosis. In women who are undecided about HRT, a low bone mineral density measurement might help convince them to start using, or to continue using, HRT. There is also a need to discuss with the patient the effect of HRT on cancer risk. In most instances, women can be reassured about the risk of endometrial cancer. The risk of breast cancer should be carefully considered and discussed with each patient before beginning HRT. In most cases, HRT should not be withheld because of fears about breast cancer, because the protective effects of HRT against cardiovascular disease and osteoporosis outweigh the possible increased risk of breast cancer. When HRT is prescribed, individual regiments should be discussed with the patient, who must be warned of the possible adverse effects. In older women, HRT can be started at half the normal dosage and tolerability assessed before increasing the dosage further.
激素替代疗法(HRT)会影响健康的多个方面:更年期症状、骨质疏松症、心血管疾病、乳腺癌和子宫内膜癌、血栓形成和栓塞以及阿尔茨海默病。是否使用HRT的决定可能取决于女性对更年期过渡、绝经后期及其后果的个人看法。因此,医疗服务提供者在文化和家庭背景下询问并讨论这些问题是很有必要的。医疗服务提供者和患者应充分了解与激素缺乏相关的症状、骨质疏松症和心血管疾病的相关风险,以及HRT预防这些疾病的潜力。最近的研究表明,HRT可能对心血管疾病风险增加(由于左心室肥厚、糖尿病、高血压或高胆固醇血症,或因吸烟)或骨质疏松症的女性特别有益。对于不确定是否使用HRT的女性,低骨密度测量可能有助于说服她们开始使用或继续使用HRT。还需要与患者讨论HRT对癌症风险的影响。在大多数情况下,可以让女性对子宫内膜癌的风险放心。在开始HRT之前,应仔细考虑并与每位患者讨论乳腺癌的风险。在大多数情况下,不应因担心乳腺癌而停用HRT,因为HRT对心血管疾病和骨质疏松症的保护作用超过了可能增加的乳腺癌风险。开具HRT处方时,应与患者讨论个体化治疗方案,必须告知患者可能的不良反应。对于老年女性,可以以正常剂量的一半开始使用HRT,并在进一步增加剂量之前评估耐受性。